DGAP-News: Press Release 4SC AG: Dr Jörg Neermann announces resignation from Supervisory Board of 4SC AG
(firmenpresse) - DGAP-News: 4SC AG / Key word(s): Change of Personnel/Miscellaneous
Press Release 4SC AG: Dr Jörg Neermann announces resignation from
Supervisory Board of 4SC AG
02.05.2012 / 10:04
---------------------------------------------------------------------
Press Release
4SC AG: Dr Jörg Neermann announces resignation from Supervisory Board
Planegg-Martinsried, Germany, 2 May 2012 - 4SC AG (Frankfurt, Prime
Standard: VSC), a discovery and development company of targeted small
molecule drugs for autoimmune diseases and cancer, today announced that Dr
Jörg Neermann has informed the company that he will resign from his
position as chairman and member of the Supervisory Board of 4SC AG
effective 31 May 2012. Dr Neermann is resigning of his own accord and for
personal reasons. Dr Neermann has been a member of the Supervisory Board of
4SC AG since 3 August 2000 and previously had been a member of the Advisory
Board of the predecessor company, 4SC GmbH.
4SC thanks Dr Neermann for his many years of commendable service and his
dedication to the work of the Supervisory Board. Dr Thomas Werner, deputy
chairman of the Supervisory Board of 4SC AG, will be assuming the position
of chairman of the Supervisory Board on an interim basis from 1 June 2012.
Following the departure of Dr Neermann, the Supervisory Board will initiate
proceedings for the election of a new Supervisory Board chairman and deputy
chairman as soon as possible.
Dr Thomas Werner, deputy chairman of the 4SC Supervisory Board, said: 'Dr
Neermann has made an outstanding contribution to the company's prestige and
to the establishment of 4SC as one of Germany's most innovative
biotechnology companies. We regret that Dr Neermann will be leaving us and
thank him for his dedication over the years and his successful work as
chairman of the 4SC Supervisory Board.'
Dr Ulrich Dauer, Chief Executive Officer of 4SC AG, commented: 'Dr Neermann
has contributed invaluable support to and had decisive impact on the
successful development of 4SC for over 13 years. Not only as an investor in
all of the company's rounds of venture capital financing, from the initial
financing in 1999 to the public listing in 2005, but also as a member -
and, from 2003, as chairman - of the 4SC Supervisory Board. On behalf of
the entire 4SC Management Board and the entire company, I wish to thank Dr
Neermann for his magnificent contribution to 4SC's success and for his
dedicated and constructive collaboration as a friend of our company. I wish
him all the best for the future.'
Ends
About 4SC
The Group managed by 4SC AG (ISIN DE0005753818) discovers and develops
targeted, small-molecule drugs for treating diseases with a high unmet
medical need in various autoimmune and cancer indications. These drugs are
intended to provide innovative treatment options that are more tolerable
and efficacious than existing therapies, and provide a better quality of
life. The Company's balanced pipeline comprises promising products that are
in various stages of clinical development. 4SC's aim is to generate future
growth and enhance its enterprise value by entering into partnerships with
leading pharmaceutical companies. Founded in 1997, 4SC had 96 employees at
the end of 2011. 4SC AG has been listed on the Prime Standard of the
Frankfurt Stock Exchange since December 2005.
Legal Note
This document may contain projections or estimates relating to plans and
objectives relating to our future operations, products, or services; future
financial results; or assumptions underlying or relating to any such
statements; each of which constitutes a forward-looking statement subject
to risks and uncertainties, many of which are beyond our control. Actual
results could differ materially, depending on a number of factors.
For more information please visit www.4sc.com or contact:
4SC
Jochen Orlowski, Investor Relations&Public Relations
jochen.orlowski(at)4sc.com, Tel.: +49 (0) 89 70 07 63 66
MC Services
Raimund Gabriel
raimund.gabriel(at)mc-services.eu , Tel.: +49 (0) 89 21 02 28 30
Mareike Mohr
mareike.mohr(at)mc-services.eu, Tel.: +49 (0) 89 21 02 28 40
The Trout Group (USA)
Chad Rubin
Crubin(at)troutgroup.com, Tel.: +1 646 378 2947
End of Corporate News
---------------------------------------------------------------------
02.05.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: 4SC AG
Am Klopferspitz 19a
82152 Martinsried
Germany
Phone: +49 (0)89 7007 63-0
Fax: +49 (0)89 7007 63-29
E-mail: public(at)4sc.com
Internet: www.4sc.de
ISIN: DE0005753818
WKN: 575381
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
167634 02.05.2012
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
" alt="Golden Predator Announces Resource Estimate at Brewery Creek Project of 580,000 Indicated ounces and 345,000 Inferred ounces of Gold
Datum: 02.05.2012 - 04:04 Uhr
Sprache: Deutsch
News-ID 1109437
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 264 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Press Release 4SC AG: Dr Jörg Neermann announces resignation from Supervisory Board of 4SC AG
"
steht unter der journalistisch-redaktionellen Verantwortung von
4SC AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
